Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 22, No 14S (July 15 Supplement), 2004: 534
© 2004 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Von Minckwitz, G. Articles by Kaufmann, M. Search for Related Content PubMed Articles by Von Minckwitz, G. Articles by Kaufmann, M.

Abstract

Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 trial

German Breast Group, Neu-Isenburg, Germany; Medizinische Biometrie Universität, Freiburg, Germany; University Women's Hospital, Heidelberg, Germany; Rot-Kreuz-Krankenhaus, München, Germany; University Women's Hospital, Kiel, Germany; Elisabeth Hospital, Kassel, Germany; Klinik für Senologie, Osnarbrück, Germany; University Women's Hospital, München re der Isar, Germany; City Hospital, Hanau, Germany; University Women's Hospital, Frankfurt, Germany

534

Background: Increasing evidence supports the use of GnRH analogues as adjuvant treatment in hormone sensitive, premenopausal breast cancer. However, only limited information is available in patients with node-negative disease. Methods: We randomised 771 patients to either goserelin (3.6 mg every 28 days for 2 years; n=393) or 3 cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy (500 mg/m², 40 mg/m² and 600 mg/m², days 1,8 q 29; n=378). Patients' characteristics were well balanced with 26% of the patients being 40 years or younger, 64% having a tumor size below 21mm, 79% having grade 1 or 2 tumors, and 72% receiving breast conserving surgery. 123 events were observed during a median follow up of 4.9 years. Results: The first event of failure (goserelin vs CMF) was an isolated locoregional recurrence (20 vs 18), a distant failure (35 vs 46), and death without recurrence (2 vs 2). Five-year event-free survival rates were 84.4% (95% confidence interval (CI): 80.4% to 88.5%) and 81.0% (95% CI: 76.3% to 85.7%) in the goserelin and in the CMF group, respectively. The estimated hazard ratio (intention-to-treat analysis) of goserelin vs CMF was 0.81 (95% CI: 0.56 to 1.17, P=0.24). Conclusions: Although the results of the trial are still based on relatively few observed events, they add important information to the current attempts of defining the role of medical ovarian ablation with goserelin in premenopausal patients with node-negative, hormonsensitive breast cancer.

Author Disclosure

Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca AstraZeneca AstraZeneca Germany

Abstract presentation from the 2004 ASCO Annual Meeting